BANGKOK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (“NewGen” or the “Company,” NASDAQ: NIVF), a technology-driven company building a diversified ecosystem across fertility technology, digital assets, and real estate development, today announced the appointment of award-winning Web3 legal and regulatory specialist Joshua Chu as Senior Counsel to lead the Group’s tokenization strategy, alongside the formal engagement of Evident Capital, Hong Kong’s first fully integrated, SFC-licensed tokeniza ...

– No objections raised by FDA to advancement of pilavapadin into Phase 3 development utilizing two-arm registrational studies of 10 mg daily dose compared to placebo –THE WOODLANDS, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the successful completion of the End-of-Phase 2 (EOP2) Meeting with the U.S. Food and Drug Administration (FDA) for pilavapadin in diabetic peripheral neuropathic pain (DPNP). During the meeting, the FDA raised no objections to ...

JERSEY CITY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Verisk (Nasdaq: VRSK), a leading strategic data analytics and technology partner to the global insurance industry, will report its financial results for the fourth quarter and fiscal year ended December 31, 2025, on Wednesday, February 18, 2026, before the market open. The press release, with accompanying financial information, will be posted on the Verisk investor website at http://investor.verisk.com. Verisk’s management team will host a live audio webc ...

Next-Generation Functional Beverage Platform Carrying Popular Brands Bucked Up and Ballislife Warwick, NY, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ozop Energy Solutions, Inc. (OZSCD), proudly announces that it has entered into an agreement to acquire Varon Corp, a next-generation functional beverage platform built for culture-driven scale, rapid commercialization, and capital-efficient growth across North America. “This acquisition marks a clear turning point for Ozop,” said Brian Conway, Chief Executive Officer ...

MIAMI, Jan. 21, 2026 (GLOBE NEWSWIRE) -- UMeWorld Inc. (OTC: UMEW) announced today that its common stock began trading on the OTC Markets under the new trading symbol “UMEW” effective January 21, 2026, following the effectiveness of the Company’s previously announced FINRA-approved corporate action. The corporate action included the Company’s redomiciliation from the British Virgin Islands to the State of Delaware, a change of corporate name to UMeWorld Inc., and the assignment of a new CUSIP number 90292A1 ...

Core Insights - Obagi Medical has launched the ALOHA Program aimed at driving innovation in aesthetic practices through real-world evidence and insights [1][2] - The program will support the introduction of Obagi saypha MagIQ™, the first FDA-approved injectable hyaluronic acid filler from the company, featuring high usable HA content and a predictable injection profile [1][2] Company Overview - Obagi Medical is recognized as a leading innovator in physician-dispensed skincare with over 35 years of experience, initially known for its Obagi Nu-Derm System targeting hyperpigmentation [3] - The company is the fastest-growing professional skincare brand in the U.S. as of 2024, focusing on various skin concerns including aging, photodamage, and acne [3] Program Details - The ALOHA Program will gather real-world data from diverse practice settings to demonstrate the effectiveness of Obagi saypha MagIQ™ and its skincare products in enhancing practice success and patient satisfaction [2] - Participants in the program will provide structured feedback through standardized surveys, creating a comprehensive evaluation of the new HA injectable beyond traditional clinical trials [2] Industry Context - Waldencast plc, the parent company of Obagi Medical, aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands, ensuring agility and market responsiveness [4] - The company's strategy includes leveraging operational scale and expertise in managing beauty brands to mitigate category fluctuations and enhance brand performance [4]

Group 1 - Starstream Entertainment, Inc. has successfully completed the acquisition of CityWalk e-Bike Inc., enhancing its portfolio in urban mobility solutions [1][2] - The acquisition aligns with Starstream's long-term growth objectives and commitment to delivering shareholder value [3] - CityWalk e-Bike Inc. specializes in electric bicycles and sustainable transportation solutions, focusing on the rapidly expanding market [4] Group 2 - Starstream Entertainment is a Nevada-based public company listed on the OTC Markets, historically known for entertainment production [4] - The company is undergoing a strategic transformation to enhance long-term shareholder value through broader commercial initiatives [4]

Core Viewpoint - NAPC Defense, Inc. will showcase its CornerShot USA tactical systems at the 2026 NASRO National School Safety Conference, emphasizing its role in enhancing school safety and security [1][4]. Event Participation - NAPC Defense will have an exhibit booth at the Peppermill Reno Resort from June 28 to June 30, 2026, inviting school resource officers, law enforcement, educators, and safety stakeholders to engage with the CornerShot USA system [2]. Product Features - CornerShot USA is a tactical platform that allows operators to observe and engage threats from behind cover, integrating firearm capabilities with high-resolution video and surveillance technologies for real-time assessment and information sharing [3]. - The system supports both lethal and non-lethal responses, providing options for school resource officers and police teams to manage threats while maintaining safety and situational awareness [3]. Focus on School Safety - At the NASRO conference, NAPC Defense will demonstrate how CornerShot USA can be integrated into existing safety protocols to improve response times and accuracy while minimizing initial exposure to threats [4]. - The company will also present training concepts that combine CornerShot deployment with practical exercises to enhance protection for students and staff during real-world threats [4]. Company Overview - NAPC Defense, Inc. is a licensed U.S. defense manufacturer with exclusive rights to produce and sell the CornerShot USA system, conducting all operations under U.S. State Department approval [6].

Core Insights - StepStone Real Estate (SRE) and Blue Moon Capital Partners have completed a $250 million continuation vehicle to operate five Class A stabilized senior housing communities [1] - The partnership aims to acquire additional high-quality senior housing communities and enhance their existing portfolio [1][2] Company Overview - StepStone Group is a global private markets investment firm managing approximately $771 billion in total capital, with $209 billion in assets under management as of September 30, 2025 [3] - Blue Moon Capital Partners focuses exclusively on senior housing, investing in Independent Living, Assisted Living, and Memory Care sectors [4] Strategic Focus - SRE is committed to building its senior housing exposure by partnering with experienced operators like Blue Moon across the US and Europe [2] - The collaboration emphasizes incorporating technology into operations and advancing workforce culture to maintain market leadership in senior housing [2][3] Growth Potential - Blue Moon aims to capitalize on the expected dramatic growth in resident demand for senior housing over the next two decades [4]

Core Insights - Avacta Therapeutics has received FDA clearance for the Investigational New Drug (IND) application for FAP-Exd (AVA6103), marking a significant step in the development of this oncology drug [1][2] - The Phase 1 clinical trial will assess the safety and efficacy of FAP-Exd in patients with pancreatic cancer, cervical cancer, gastric cancer, and small cell lung cancer, utilizing an AI approach to select these tumor types [2][3] - The trial will include adult participants in a dose-escalation study with two administration schedules, with preliminary data expected in the second half of 2026 [3] Company Developments - The transition of FAP-Exd from lab to human testing within 24 months demonstrates the company's efficiency in advancing its programs [3] - The innovative sustained release mechanism of FAP-Exd aims to enhance efficacy while minimizing toxicities associated with exatecan [3] - The clinical program is expected to provide insights into the pre|CISION platform's chemistry and validate the potential for varied payloads based on novel technologies [3] Technology Overview - The pre|CISION platform is designed to deliver potent cancer therapies by concentrating them in the tumor microenvironment while sparing normal tissues [5][7] - The platform utilizes a proprietary peptide that targets fibroblast activation protein (FAP), which is upregulated in most solid tumors, allowing for optimized dosing and reduced systemic toxicity [6][7]